Other languages PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Market Closed - Australian S.E. Other stock markets 02:10:44 2024-04-26 am EDT			5-day change	1st Jan Change
0.092 ^AUD	-1.08%		+1.10%	-16.36%

Apr. 22	Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data	MT
Apr. 22	PYC Therapeutics Confirms Safety, Tolerability of Kidney Medication in Animal Study	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data	Apr. 22
PYC Therapeutics Raises AU$13.5 Million via Retail Offer; AU$21.2 Million Retail Shortfall Placement Announced	Apr. 10
PYC Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 29
PYC Therapeutics Receives AU$4.5 Million Upfront Fee for Drug Discovery Collaboration	Feb. 16
PYC Therapeutics to Launch Google Cloud-Hosted Drug Discovery Project; Shares Fall 5%	Jan. 01
Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease	Nov. 13
PYC Therapeutics Completes Dosing in Second Patient Cohort for Retinitis Pigmentosa Clinical Trial	Nov. 03
PYC Reports Positive Results from Preclinical Studies of Rare Eye Disease Drug	23-10-05
PYC Therapeutics Advances to Second Dose Cohort of Phase 1 Trial Following Safety Clearance	23-09-22
PYC Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31
PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program	23-08-11
PYC Therapeutics' RP11 Investigational Drug Candidate Secures Fast Track Designation from US FDA; Shares Climb 3%	23-08-01
PYC Therapeutics Doses First Patient in Blinding Eye Disease Trial	23-06-29
Pyc Appoints Andrew Taylor as Joint Company Secretary	23-06-01
PYC Therapeutics to Raise AU$30 Million in Placement	23-05-11
PYC Therapeutics Secures US FDA Clearance to Start Retinitis Pigmentosa Trial	23-03-06
Us Fda Clears PYC Therapeutics Limited to Commence the First Ever Human Trial in Retinitis Pigmentosa Type 11	23-03-05
PYC Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-28
PYC Therapeutics Files IND Application with US FDA for Retinitis Pigmentosa Medication	23-02-02
PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration	23-02-01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Other languages

Filters